Generac (NYSE:GNRC) executives highlighted accelerating momentum in the data center market alongside a weak late-2025 outage environment that pressured residential generator demand, as the company ...
Fewer power outages led to disappointing residential sales for Generac, but investors cheered the jump in sales to data centers Generac shares soared as an upbeat outlook on sales to data centers ...
Generac Holdings Inc. (NYSE: GNRC) (“Generac” or the “Company”), a leading global designer and manufacturer of energy technology solutions and other power products, today reported financial results ...
Generac Holdings Inc. (NYSE: GNRC) ("Generac" or the "Company"), a leading global designer and manufacturer of energy technology solutions and other ...
Generac Holdings Inc. ('Generac') (NYSE: GNRC), a leading global designer, manufacturer, and provider of energy technology solutions and other power products, today announced plans to release its ...
House Digest on MSN
11 best generators to have on hand in case of emergencies, based on reviews
Even though power outages aren't an ordinary occurrence, it still pays to be prepared in case of an emergency -- hence the ...
If you bought your first generator or propane heater, there are a couple of things you should know about safely operating ...
Acadia Healthcare — The health-care stock popped 10% after investor David Einhorn told CNBC that he has been buying the stock. The Greenlight Capital fund manager said he's hopeful the company's new ...
The portable generators market is a dynamic sector witnessing steady growth driven by a myriad of factors including increasing demand for reliable power backup solutions, rising frequency of power ...
The Philadelphia region, once a banking center, is still home to financial innovators. One of the growing digital lenders based nearby is seven-year-old PowerPay, whose 225 staff members build a ...
The 4-bedroom residence features a chef's kitchen, heated saltwater pool with waterfall, and sits high above surrounding ...
Moderna — Shares tumbled 10% after the pharma giant said the Food and Drug Administration refused to review its application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results